Princz-Lebel, Oren
Attaran, Anoosha
Sandoval Contreras, Rodrigo https://orcid.org/0009-0000-1167-2513
Novikov, Vladislav
Panjwani, Samina
Chu, Anthony https://orcid.org/0009-0003-9363-698X
Tan, Cherisse https://orcid.org/0000-0002-3945-1015
Lemieux, Claire A.
Skirzewski, Miguel https://orcid.org/0000-0002-0980-0878
Machado, Meira M. F. https://orcid.org/0000-0003-4619-5782
Watts, Joel C. https://orcid.org/0000-0002-2604-2925
McPhail, Jacob A. https://orcid.org/0000-0003-1490-808X
Louwrier, Ariel
Prado, Vania F. https://orcid.org/0000-0003-4994-6393
Saksida, Lisa M. https://orcid.org/0000-0002-8416-8171
Prado, Marco A. M. https://orcid.org/0000-0002-3028-5778
Bussey, Timothy J. https://orcid.org/0000-0002-3180-3709
Article History
Received: 8 November 2024
Revised: 3 December 2025
Accepted: 15 December 2025
First Online: 9 January 2026
Competing interests
: Jacob A. McPhail generated and characterized the recombinant alpha-synuclein pre-formed fibrils while an employee of StressMarq Biosciences, and Ariel Louwrier is the founder of StressMarq Biosciences. The authors declare that they have no other competing interests. Timothy J. Bussey and Lisa M. Saksida have established a series of targeted cognitive tests for animals, administered via touchscreen with a custom environment known as the “Bussey-Saksida touchscreen chamber”. Cambridge Enterprise, the technology transfer office of the University of Cambridge, supported commercialisation of the Bussey-Saksida chamber, culminating in a license to Campden Instruments. Any financial compensation received from commercialisation of the technology is fully invested in further touchscreen development and/or maintenance. All other authors declare no competing interests.
: All procedures were conducted in accordance with the relevant guidelines and regulations, including the Canadian Council on Animal Care (CCAC) guidelines, and were approved by the Animal Care and Veterinary Services (ACVS) at Western University (protocol #2020-162 and #2020-163). All methods were performed in compliance with the ARRIVE guidelines.